FDA Approves Onswik (Insulin Efsitora Alfa-gobe), a Second Once-Weekly Insulin, for Adults With Type 2 Diabetes

The FDA approved Onswik (insulin efsitora alfa-gobe) to improve glycemic control in adults with type 2 diabetes mellitus. The FDA Novel Drug Approvals for 2026 page lists the approval date as September 23, 2026, and that is the date used in this post.

The FDA approval summary describes Onswik as the second once-weekly insulin approved for adults with type 2 diabetes. The summary also states that the product is not recommended for patients with type 1 diabetes, a limit reported here as part of the FDA record.

The date record has the same pattern seen with other 2026 approvals. Lilly announced the approval on September 24, 2026, and the FDA approval summary page is published on September 24, while the FDA approvals lists give September 23. The list date controls here.

Insulin is a peptide hormone, so this event is included for completeness in a peptide-focused backfill. Readers who follow only non-insulin peptides can treat the insulin approvals in this series as a separate, clearly labeled group.

As with every FDA approval, the decision applies to the specific product, Onswik, and the specific indication on its label. It does not extend to compounded formulations, research compounds, or any other insulin product.